As part of the latest digital supplement to Value & Outcomes Spotlight, the International Society of Outcomes Research (ISPOR), published a series of editorials and articles on the need for the adoption of a more holistic approach towards Alzheimer’s disease (AD) treatments.
One of the articles focuses on the work of the Innovative Medicines Initiative (IMI) funded ROADMAP project.
The “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform” (ROADMAP) project aimed to provide the foundation for an integrated data environment and framework for real-world evidence (RWE in Alzheimer’s disease).
This included the development of consensual key outcome measures and enabling data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP had a budget of EUR 8.21 million and 26 partners led by the University of Oxford and Novartis. The project ran from September 2016 till October 2018.
Long-Term Value Demonstration in Alzheimer’s Disease: Evidence Needs
The article focuses on different topics, encompassing:
- The Need for Long-Term Value Demonstration in Alzheimer’s Disease
- Evidence Needs for Early Detection and Diagnosis
- Data Gaps: Assessing Needs in Real-World Evidence
- Potential Solutions: Identifying Focus Areas for Long-Term Value Demonstration
- Next Steps: Building a Foundation of Long-Term Value Demonstration and the Potential Role of Innovative Payment Models
- Preparing for the Future of Long-Term Alzheimer’s Value Assessment
The supplement can be downloaded here: https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/valuing-future-alzheimers-disease-treatments-the-need-for-a-holistic-approach/